

Re-inventing access to biologics

Brussels, July 2023

Univercells develops breakthrough technologies and services that democratize the production of biologics.

So that everyone, everywhere has access to the medicines they need, when they need them.

Univercells widens access to biologics through innovative technology, manufacturing and advisory services



Univercells

Revenues¹

FTEs¹

Univercells serves many market segments across biologics through integrated solutions and services across three areas

GROUP – TECHNOLOGY – CDMO – ADVISORY



TECHNOLOGY

- Development & industrialization of intensified and scalable technology portfolio to enable partners to achieve low cost, low footprint, high-quality and high-performance production
- Applications in DNA and RNA from R&D to commercial



CDMO

- Designing and operating bespoke bioproduction hubs with state-of-the-art technology (including proprietary biomanufacturing technologies)
- Product & process development expertise for therapy innovators in C>, vaccines, DNA/RNA across all phases: from pre-clinical to GMP manufacturing and tech transfer



ADVISORY


- Opening new markets by providing turnkey services to support emerging players wherever biologics can make a difference, making local bioproduction a reality
- From **design to operations** of bioproduction sites, tech transfer, workforce development, product licenses and regulatory affairs






Univercells develops biomanufacturing technologies based on proven intensification & chaining fundamentals

GROUP - TECHNOLOGY - CDMO - ADVISORY



Univercells delivered a high-performing disruptive viral vector biomanufacturing technology and replicated this success in DNA/RNA


GROUP - TECHNOLOGY - CDMO - ADVISORY




Univercells was selected as key technology partner by the WHO for the mRNA vaccine transfer hub aiming at locally produced & owned mRNA

GROUP - TECHNOLOGY - CDMO - ADVISORY









We have invested in proprietary infrastructure, leveraging our technology background to offer customers unparalleled expertise



CDMO



Viral vector CDMO

Using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies



Nucleic Acids CRDMO

Leveraging an optimal process that can take your therapeutic at high quality and high speed from discovery up to production



BIOPROCESSING EXPERTISE AND PLATFORMS







Adapted approach to customer's needs, delivering complex projects more quickly and cost-effectively for viral vectors and nucleic acids GROUP - TECHNOLOGY - CDMO - ADVISORY

At Exothera it's not just what we do but how we do it that makes us different

Capability stack



State-of-the-art facilities

Scalable platforms in one facility from pre-clinical to GMP manufacturing for viral vector and nucleic acid production



Technology

The choice of cuttingedge suspension or adherent cell culture technologies for viral vectors & scalable platform for nucleic acids



Expertise

~150 experts in process development and viral vector/RNA manufacturing, having developed groundbreaking technologies



Quality driven

Every stage of the process is designed with quality in mind



Agility

Tailored and highly responsive, focusing on our clients' needs



17,000m² unique CDMO facilities were deployed in record time and received GMP certification in 2022

A REAL PROPERTY AND A PARTY OF A

WNIVERCELLS


Vega facility

Nova facility

ECONDERENCES

Our advisory services provide support to emerging players, expanding biomanufacturing capacity globally & building our future customer base

GROUP - TECHNOLOGY - CDMO - ADVISORY (Case Study)



Biologics available to all!



Contact Us

This report has been produced by Univercells in July 2023.

While the information provided herein is believed to be accurate, Univercells makes no representation or warranty, express or implied, as to the accuracy or completeness of such information. The information contained herein was prepared expressly for use herein and is based on certain assumptions and information available at the time this report was prepared. There is no representation, warranty or other assurance that any of the projections or estimates will be realized, and nothing contained within this report is or should be relied upon as a promise or representation as to the future. In furnishing this report Univercells reserves the right to amend or replace the report at any time and undertakes no obligation to provide the users with access to any additional information.



Univercells HQ All. Centrale - Zoning de Jumet 52, 6040 Charleroi

info@univercells.com